{
  "id": 14211019,
  "title": "Truist cuts Nurix stock price target to $33 on model adjustments",
  "url": "https://urgent.news/2026/10/13/truist-cuts-nurix-stock-price-target-to-33-on-model-adjustments",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-13T13:50:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/truist-cuts-nurix-stock-price-target-to-33-on-model-adjustments-93CH-4947007"
  },
  "original_language": "en",
  "account": "Truist Securities has revised its price target for Nurix Therapeutics shares, lowering it to $33 from the previous $34 valuation. Despite the adjustment, the firm maintains a Buy rating for the stock, currently trading at $22.47. In the preceding year, Nurix shares have delivered a strong 128% return. Analysts at InvestingPro assess the stock as slightly undervalued, with strong buy ratings and target prices spanning from $25 to $45. Truist's financial model adjustments came after Nurix's third-quarter fiscal 2026 earnings report and a subsequent call with management. Greg Renza, a Truist analyst, highlighted advancements in Nurix's lead bexdeg programs, including the initiation of phase III CLL-306 head-to-head study against pirtobrutinib and phase Ib/II CLL-203 combination studies. Nurix plans to explore multiple sclerosis and chronic spontaneous urticaria indications via partnerships with Roche. The company anticipates phase IIb data from partner KT-621's STAT6 program in late November or early December, which could impact Nurix and Sanofi's STAT6 program. Truist's decision to reduce the price target appears to be based on the company's prioritization of bexdeg, with zelebrudomide's discontinuation being expected. Truist believes the advancement of NX-1607 adds a positive increment, although it remains a modest contributor to their financial model. In related news, Morgan Stanley has increased its price target for Nurix shares to $38.00, maintaining an Overweight rating, while Mizuho has raised its target to $34 from $30, keeping an Outperform rating. These moves follow Nurix's significant deal with Roche and its latest earnings report and pipeline update. Despite these developments, analysts remain optimistic about Nurix's future performance.",
  "summary": null,
  "key_points": [
    "Truist cuts Nurix stock price target to $33 from $34",
    "Nurix shares up 128% in the past year",
    "Analysts note bexdeg program advancements"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Truist reiterates Buy on Scholar Rock stock, $77 target on launch",
        "url": "https://urgent.news/2026/10/13/truist-reiterates-buy-on-scholar-rock-stock-77-target-on-launch",
        "published": "2026-10-13T13:50:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}